Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q3 2024 · 10-Q
Revenue$40.90M$40.90M+458.8% vs Q3 2023 Net Income-$17.62M-$17.62MN/M vs Q3 2023 EPS Diluted-$0.01-$0.01N/M vs Q3 2023 Operating Income-$14,680,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$54,594,000N/M Margins · derivedOperating margin-35.9%+601.3 pt vs Q3 2023
Net margin-43.1%+580.0 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end